• This email address is being protected from spambots. You need JavaScript enabled to view it.
  • Sun - Fri 8:00 - 20:30
 MGI TECH

MGI launched new nanopore sequencing products featuring advanced CycloneSEQ technology

MGI Tech Co., Ltd. a company committed to building core tools and technologies that drive innovation in life science, announced the global rights to commercialize and distribute the new sequencing products CycloneSEQ-WT02* and CycloneSEQ-WY01*. With potential across different areas of genomics, CycloneSEQ™ technology integrates numerous technological improvements, including advanced protein engineering, a novel flow cell design, and a cutting-edge basecalling algorithm, to enable high accuracy and throughput in sequencing.

Read more →
Niagen+ NAD+ Test Kit

ChromaDex Launched Niagen+ NAD+ Test Kit Available Exclusively to Health Care Practitioners (HCPs)

ChromaDex Corp. the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, launches the Niagen+ NAD+ Test Kit*, now available exclusively through the company’s healthcare practitioner (HCP) channel. This innovative test kit provides practitioners with a reliable method for measuring patient blood NAD+ levels, helping them create more personalized and effective patient protocols using ChromaDex’s NAD+-boosting HCP products, Tru Niagen® and Niagen+.

Read more →
Palonosetron Hydrochloride Injection

Avenacy Announces Launch of Palonosetron Hydrochloride Injection, USP in the U.S. Market

Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, announced it has launched Palonosetron Hydrochloride Injection, USP in the United States as a therapeutic generic equivalent for Aloxi® as approved by the U.S. Food and Drug Administration. Palonosetron Hydrochloride Injection, USP is indicated as an antiemetic.

Read more →